Zalutumumab
Term · Oncology and biomedicine · MLC-T-ONC-017648
A fully human IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Zalutumumab selectively binds to the EGFR receptor and blocks receptor binding of EGF and transforming growth factor-alpha (TGF-a), which results in the disruption of EGFR-mediated cell signaling, cell growth inhibition and apoptosis in EGFR-expressing tumor cells. In addition, this agent triggers antibody dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. EGFR is a cell surface receptor tyrosine kinase, overexpressed on many cancer cells.
| Identifier | MLC-T-ONC-017648 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-017648",
"term": "Zalutumumab",
"field": "Oncology and biomedicine",
"definition": "A fully human IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Zalutumumab selectively binds to the EGFR receptor and blocks receptor binding of EGF and transforming growth factor-alpha (TGF-a), which results in the disruption of EGFR-mediated cell signaling, cell growth inhibition and apoptosis in EGFR-expressing tumor cells. In addition, this agent triggers antibody dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. EGFR is a cell surface receptor tyrosine kinase, overexpressed on many cancer cells.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/zalutumumab/"
}
Record 17,591 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.